<DOC>
	<DOCNO>NCT00477802</DOCNO>
	<brief_summary>The primary objective study determine whether intramuscular injection botulinum toxin type A ( Botox® ) select cervical muscle antidystonic dosage reduce levodopa-induced peak-dose dyskinesia ( LID ) cervical region adult patient idiopathic Parkinson 's disease . It hypothesize intramuscular injection antidystonic dos botulinum toxin cervical muscle decrease duration severity LID cervical region patient Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Botulinum Toxin Type A ( Botox ) Management Levodopa-Induced Peak-Dose Dyskinesias Parkinson 's Disease</brief_title>
	<detailed_description>The study follow cross-over design maximize statistical power decrease bias inherent small sample patient become control . After baseline assessment , patient randomize receive either botulinum toxin equal amount distribution normal saline ( placebo ) . Patients undergo reassessment function one four week initial second session injection . The second procedure occur , use opposite treatment arm ( Botox® saline placebo ) , three month first injection session . Doses levodopa , dopaminergic agonist , antidyskinetic drug applicable , keep constant throughout study . All study assessment carry time treatment expect cause great severity LID .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Patients must idiopathic PD ( standard clinical criterion ) . 2 . Patients must persistence LID despite optimization antiParkinsonian medication ( duration LID &gt; 1 [ duration least 125 % waking time ] item 32 United Parkinson 's Disease Rating Scale [ UPDRS ] ) . 3 . Patients must severity LID &gt; 1 [ mildly disable ] item 33 UPDRS . 4 . Patients must MiniMental State score &gt; 24 . 5 . Patients must willing able give consent . 1 . Patients older 75 year age . 2 . Patients Parkinsonian syndrome unresponsive weakly responsive levodopa ( improvement &lt; 30 % ) . 3 . Patients require concurrent use warfarin anticoagulating agent . 4 . Uncontrolled clinically significant medical condition condition evaluation 5 . Known allergy sensitivity component study medication . 6 . Concurrent participation another investigational drug device study participation 30 day immediately prior study enrollment . 7 . Any medical condition may put subject increase risk exposure Botox include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , disorder might interfere neuromuscular function . 8 . Evidence recent alcohol drug abuse . 9 . Infection skin disorder anticipate injection site ( applicable ) . 10 . Any condition situation , investigator 's opinion , may put subject significant risk , confound study result , interfere significantly subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>levodopa-induced cervical dyskinesia</keyword>
</DOC>